Abstract 520P
Background
With the advent of targeted therapy in modern oncology, dramatic changes have occurred in approaches to cancer treatment. One of the promising areas is agnostic antitumor therapy, which is aimed at treating solid tumors without taking into account their type and location. In our work, we examined the presence of these biomarkers in a group of patients according to Precision Medicine Working Group recommendations (2024).
Methods
146 paired DNA and RNA (for fusions detection) was isolated from FFPE. NGS was performed using Oncomine Focus/ Comprehensive assay on the Ion S5 Plus Sequencing platform. The data were analized via Torrent Suite and Ion Reporter Softwares.
Results
At least one biomarker was found in 15 (7.5%) out of 146 patients with solid various types tumors. The biomarkers were distributed as follows: 33% of findings were for BRAF V600E mutations, 27% each for MSI-H and FGFR gene mutations. RET gene mutations accounted for 13% of the results. Mutations of NTRK genes were not found in our sample group. Important note is that TMB and MSI status were not accessed for entire sample group, Across 26 patients with MSI testing: 46% had MSS status, 38% -MSI-L status. And 15% were MSI-H. Biomarkers were predominantly found in CRC -36%, in 14% of cases, biomarkers were found in patients with thyroid cancer or lung cancer. Solitary cases of breast, head and neck and glioblastoma had also biomarkers for agnostic treatment options. All samples were accessed based on the number of findings per patient: 1 finding was predominant – 42%, 2 – 19%, 3 – 7%, 4 – 5%. There were also solitary cases of patients with 5 and 8 mutations.
Conclusions
Tumor-agnostic approach by multigene NGS in patients with advanced cancers is promising, giving an every 15 patient a chance to be specifically treated. The findings were mostly detected in those types of cancer, where NGS could be routinely used due to several potential findings, it can be really important to broadly use this type of testing in other especially rare cancers where the targeted therapy in dot broadly used. Comprehensive NGS testing for current tumor-agnostic biomarkers with co-findings searching for molecular resistance mechanisms may shed some light making the list of biomarkers wider and options for treatment greater.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
First Genetics JSC.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.